{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:20:50Z","timestamp":1761549650496,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.nano.2022.102527","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T20:02:24Z","timestamp":1643486544000},"page":"102527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response"],"prefix":"10.1016","volume":"41","author":[{"given":"Qiong","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.nano.2022.102527_bb0010","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.15585\/mmwr.mm7038e2","article-title":"Use of Pfizer-BioNTech COVID-19 vaccine in persons aged \u226516 years: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, September 2021","volume":"70","author":"Dooling","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.nano.2022.102527_bb0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.nano.2022.102527_bb0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.nano.2022.102527_bb0045","first-page":"1","article-title":"Vaccine efficacy in mutant SARS-CoV-2 variants","volume":"4","author":"Kandikattu","year":"2021","journal-title":"Int J Cell Biol Physiol"},{"issue":"7","key":"10.1016\/j.nano.2022.102527_bb0050","first-page":"e285","article-title":"Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2. Lancet","volume":"2","author":"Huang","year":"2021","journal-title":"Microbe"},{"issue":"7","key":"10.1016\/j.nano.2022.102527_bb0055","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41422-021-00514-9","article-title":"Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines","volume":"31","author":"Cao","year":"2021","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.nano.2022.102527_bb0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta)","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"Variant N Engl J Med"},{"key":"10.1016\/j.nano.2022.102527_bb0065","article-title":"Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies","author":"Wilhelm","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.nano.2022.102527_bb0070","unstructured":"Pulliam JRC vSC, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv [Preprint]."},{"key":"10.1016\/j.nano.2022.102527_bb0075","article-title":"Covid-19: omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear","volume":"375","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.nano.2022.102527_bb0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance","volume":"62","author":"Chen","year":"2022","journal-title":"J Chem Info Model"},{"issue":"7798","key":"10.1016\/j.nano.2022.102527_bb0090","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"6483","key":"10.1016\/j.nano.2022.102527_bb0095","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.nano.2022.102527_bb0100","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/21645515.2020.1740560","article-title":"Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19","volume":"16","author":"Chen","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.nano.2022.102527_bb0105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"issue":"2","key":"10.1016\/j.nano.2022.102527_bb0110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.nano.2022.102527_bb0115","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"key":"10.1016\/j.nano.2022.102527_bb0120","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3389\/fimmu.2018.01043","article-title":"Peptide vaccines for leishmaniasis","volume":"9","author":"De Brito","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.nano.2022.102527_bb0125","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/cas.13506","article-title":"Present status and future perspective of peptide-based vaccine therapy for urological cancer","volume":"109","author":"Obara","year":"2018","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.nano.2022.102527_bb0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tranon.2019.02.008","article-title":"Cancer-testis antigen peptide vaccine for cancer immunotherapy: progress and prospects","volume":"12","author":"Wei","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.nano.2022.102527_bb0135","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.R120.002309","article-title":"The peptide vaccine of the future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"10.1016\/j.nano.2022.102527_bb0140","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.arcmed.2021.01.004","article-title":"Immunoinformatics approach for the identification and characterization of T cell and B cell epitopes towards the peptide-based vaccine against SARS-CoV-2","volume":"52","author":"Chakraborty","year":"2021","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1016\/j.nano.2022.102527_bb0145","article-title":"Immunoinformatic analysis of T- and B-cell epitopes for SARS-CoV-2 vaccine design","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.nano.2022.102527_bb0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2","volume":"27","author":"Grifoni","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.nano.2022.102527_bb0155","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-020-16638-2","article-title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients","volume":"11","author":"Poh","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2022.102527_bb0160","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.actbio.2019.09.024","article-title":"Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer","volume":"100","author":"Feng","year":"2019","journal-title":"Acta Biomater"},{"issue":"6499","key":"10.1016\/j.nano.2022.102527_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.nano.2022.102527_bb0170","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.nano.2022.102527_bb0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human Primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect Dis"},{"issue":"16","key":"10.1016\/j.nano.2022.102527_bb0180","doi-asserted-by":"crossref","first-page":"8193","DOI":"10.1128\/JVI.00133-15","article-title":"Nonglycosylated G-protein vaccine protects against homologous and heterologous respiratory syncytial virus (RSV) challenge, while glycosylated G enhances RSV lung pathology and cytokine levels","volume":"89","author":"Fuentes","year":"2015","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.nano.2022.102527_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061717","article-title":"Protein polymer-based nanoparticles: fabrication and medical applications","volume":"19","author":"DeFrates","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.nano.2022.102527_bb0190","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1039\/C9NR10334A","article-title":"Local mucosal immunization of self-assembled nanofibers elicits robust antitumor effects in an orthotopic model of mouse genital tumors","volume":"12","author":"Li","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.nano.2022.102527_bb0195","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.2147\/IJN.S214525","article-title":"Self-assembled nanofibers elicit potent HPV16 E7-specific cellular immunity and abolish established TC-1 graft tumor","volume":"14","author":"Li","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2022.102527_bb0200","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2147\/IJN.S237182","article-title":"Virus-like particles presenting the FGF-2 protein or identified antigenic peptides promoted antitumor immune responses in mice","volume":"15","author":"Shu","year":"2020","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"10.1016\/j.nano.2022.102527_bb0205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/acsnano.0c03023","article-title":"Glycan-modified virus-like particles evoke T helper type 1-like immune responses","volume":"15","author":"Alam","year":"2021","journal-title":"ACS Nano"},{"issue":"13","key":"10.1016\/j.nano.2022.102527_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108915","article-title":"Linear epitope landscape of the SARS-CoV-2 spike protein constructed from 1,051 COVID-19 patients","volume":"34","author":"Li","year":"2021","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.nano.2022.102527_bb0215","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1164\/rccm.200610-1405OC","article-title":"Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice","volume":"176","author":"Ma","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"6510","key":"10.1016\/j.nano.2022.102527_bb0220","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:16:42Z","timestamp":1761549402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963422000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":38,"alternative-id":["S1549963422000132"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2022.102527","relation":{},"ISSN":["1549-9634"],"issn-type":[{"type":"print","value":"1549-9634"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2022.102527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102527"}}